Optimization Strategies of Transcranial Magnetic Stimulation in Major Depressive Disorder

ALPHA PSYCHIATRY, Journal Year: 2024, Volume and Issue: 24(6), P. 270 - 272

Published: Jan. 4, 2024

Language: Английский

---

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)

Psychiatry Research, Journal Year: 2023, Volume and Issue: 327, P. 115378 - 115378

Published: July 29, 2023

Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA FDA, but data about predictors of response are still lacking. Thus, tool that can predict the individual patients' probability to ESK-NS is needed. This study investigates sociodemographic features predicting responses in patients using machine learning techniques. In retrospective, multicentric, real-world involving 149 subjects, psychometric (Montgomery-Asberg-Depression-Rating-Scale/MADRS, Brief-Psychiatric-Rating-Scale/BPRS, Hamilton-Anxiety-Rating-Scale/HAM-A, Hamilton-Depression-Rating-Scale/HAMD-17) were collected at baseline one month/T1 three months/T2 post-treatment initiation. We trained different random forest classifiers, able accuracies 68.53% T1 66.26% T2 remission 68.60% accuracy. Features like anhedonia, anxious distress, mixed symptoms as well bipolarity found positively remission. At same time, benzodiazepine usage severity linked delayed responses. Despite some limitations (i.e., retrospective study, lack biomarkers, correct interrater-reliability across centers), these findings suggest potential personalized intervention TRD.

Language: Английский

---

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Journal of Affective Disorders, Journal Year: 2023, Volume and Issue: 348, P. 314 - 322

Published: Dec. 23, 2023

Language: Английский

---

Stanford neuromodulation therapy for treatment-resistant depression: a systematic review

Frontiers in Psychiatry, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 13, 2023

Objective This systematic review of randomized controlled studies (RCTs) and observational evaluated the efficacy safety stanford neuromodulation therapy (SNT) for patients with treatment-resistant depression (TRD). Methods A search (up to 25 September, 2023) RCTs single-arm prospective was conducted. Results One RCT ( n = 29) three 34) met study entry criteria. In RCT, compared sham, active SNT significantly associated higher rates antidepressant response (71.4% versus 13.3%) remission (57.1% 0%). Two out reported percentage after completing SNT, ranging from 83.3% (5/6) 90.5% (19/21). studies, ranged 66.7% (4/6) No severe adverse events occurred in all four studies. Conclusion found improved depressive symptoms TRD within 5 days, without events.

Language: Английский

---

Dopaminergic dysfunction in the left putamen of patients with major depressive disorder

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 357, P. 107 - 115

Published: April 16, 2024

Language: Английский

---

Efficacy of Combined Theta Burst Stimulation (TBS) and Intranasal Esketamine in an ECT-Resistant Depressive Patient: A Case Report

Psychiatry Research Case Reports, Journal Year: 2025, Volume and Issue: unknown, P. 100250 - 100250

Published: Feb. 1, 2025

Language: Английский

---

Advances in repetitive transcranial magnetic stimulation in the treatment of treatment-resistant depression: a comprehensive review

Reviews in the Neurosciences, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 13, 2025

Abstract Major depressive disorder is a common mental disorder, and significant number of patients exhibit poor response to conventional antidepressant treatments, known as treatment-resistant depression (TRD). However, the definition TRD globally remains unclear, impeding clinical research, treatment development, outcome implementation, policy-making. A wealth research confirms that rTMS demonstrates promising efficacy in TRD. This paper elucidates TRD, summarizes potential targets for treating comprehensively elaborates on unique mechanisms, efficacy, side effects outlines considerations special populations receiving well other modalities Through these studies, we aim provide more scientifically grounded recommendations undergoing

Language: Английский

---

Esketamine Nasal Spray Compassionate Use Program in the Netherlands: an open Label, Multi-Center Cohort Study in Severe Treatment-Resistant Depression

Journal of Affective Disorders Reports, Journal Year: 2025, Volume and Issue: unknown, P. 100905 - 100905

Published: April 1, 2025

Language: Английский

---

Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database

Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(6), P. 567 - 578

Published: April 27, 2024

Objective: The study aimed to conduct a multidimensional evaluation of potential adverse events (AEs) escitalopram oxalate based on the FDA event reporting system (FAERS) database. Methods: This utilized odds ratio (ROR), proportional (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-poisson shrinker (MGPS) mine analyze data from FAERS database first quarter 2004 second 2023. Results: There was total 19,854 AE reports related oxalate, extracting 625 preferred terms (PTs), covering 27 organ classes (SOCs). results showed that number by females significantly higher than males, accounting for 57.68%. in 2018 2019, 9.50% 10.18% reports, respectively. main reporters were consumers other health professionals, 26.99% 26.75% majority primarily United States. Newly emerging signals such as intentional overdose ( n = 691, ROR 8.51, PRR 8.45, IC 3.05, Empirical Geometric Mean (EBGM) 8.35), suicide attempt 665, 8.58, 8.52, 3.06, EBGM 8.42), serum serotonin 5, 1044.78, 1044.71, 2.56, 392.39), anti-actin antibody positive 626.87, 626.83, 313.91), among others, not mentioned drug’s label. Conclusion: While has clear benefits treatment depression mental disorders, presence AEs also suggests risks associated with its use. Particularly concerning are changes levels.

Language: Английский

---

Overcoming treatment-resistant depression with machine-learning based tools: a study protocol combining EEG and clinical data to personalize glutamatergic and brain stimulation interventions (SelecTool Project)

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15

Published: July 17, 2024

Treatment-Resistant Depression (TRD) poses a substantial health and economic challenge, persisting as major concern despite decades of extensive research into novel treatment modalities. The considerable heterogeneity in TRD’s clinical manifestations neurobiological bases has complicated efforts toward effective interventions. Recognizing the need for precise biomarkers to guide choices TRD, herein we introduce SelecTool Project. This initiative focuses on developing (WorkPlane 1/WP1) conducting preliminary validation 2/WP2) computational tool (SelecTool) that integrates data, neurophysiological (EEG) peripheral (blood sample) through machine-learning framework designed optimize TRD protocols. project aims enhance decision-making by enabling selection personalized It leverages multi-modal data analysis navigate towards two validated therapeutic options TRD: esketamine nasal spray (ESK-NS) accelerated repetitive Transcranial Magnetic Stimulation (arTMS). In WP1, 100 subjects with will be randomized receive either ESK-NS or arTMS, comprehensive evaluations encompassing (EEG), (psychometric scales), samples) assessments both at baseline (T0) one month post-treatment initiation (T1). WP2 utilize collected WP1 train algorithm, followed its application second, out-of-sample cohort 20 subjects, assigning treatments based tool’s recommendations. Ultimately, this seeks revolutionize employing advanced machine learning strategies thorough analysis, aimed unraveling complex landscape depression. effort is expected provide pivotal insights promote development more individually tailored strategies, thus addressing significant void current management potentially reducing profound societal burdens.

Language: Английский

---